Article

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.

Biochemisches Institut, Christian-Albrechts-Universität zu Kiel, Olshausenstr. 40, D-24098 Kiel, Germany.
Journal of Leukocyte Biology (Impact Factor: 4.3). 09/2006; 80(2):227-36. DOI: 10.1189/jlb.1105674
Source: PubMed

ABSTRACT Cytokine receptors, which exist in membrane-bound and soluble forms, bind their ligands with comparable affinity. Although most soluble receptors are antagonists and compete with their membrane-associated counterparts for the ligands, certain soluble receptors are agonists. In these cases, complexes of ligand and soluble receptor bind on target cells to second receptor subunits and initiate intracellular signaling. The soluble receptors of the interleukin (IL)-6 family of cytokines (sIL-6R, sIL-11R, soluble ciliary neurotrophic factor receptor) are agonists capable of transmitting signals through interaction with the universal signal-transducing receptor for all IL-6 family cytokines, gp130. In vivo, the IL-6/sIL-6R complex stimulates several types of cells, which are unresponsive to IL-6 alone, as they do not express the membrane IL-6R. We have named this process trans-signaling. The generation of soluble cytokine receptors occurs via two distinct mechanisms-limited proteolysis and translation-from differentially spliced mRNA. We have demonstrated that a soluble form of the IL-6 family signaling receptor subunit gp130, which is generated by differential splicing, is the natural inhibitor of IL-6 trans-signaling responses. We have shown that in many chronic inflammatory diseases, including chronic inflammatory bowel disease, peritonitis, rheumatoid arthritis, asthma, as well as colon cancer, IL-6 trans-signaling is critically involved in the maintenance of a disease state, by promoting transition from acute to chronic inflammation. Moreover, in all these models, the course of the disease can be disrupted by specifically interfering with IL-6 trans-signaling using the soluble gp130 protein. The pathophysiological mechanisms by which the IL-6/sIL-6R complex regulates the inflammatory state are discussed.

1 Follower
 · 
104 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Greater than 50,000 new cases of breast cancer cases were diagnosed in Italy during 2013, with nearly 15,000 women succumbing to the disease. These epidemiological statistics highlight the overwhelming clinical dilemma of breast cancer and emphasize the need for novel therapeutic targets and prevention strategies. Countless studies in the fields of mammary gland development and breast cancer have led to an appreciation of a breast tumor microenvironment that actively contributes to the heterogeneous nature of breast cancer. The current review will focus on the impact of IL-6 and in the breast tumor microenvironment. Excessive IL-6 has been demonstrated in primary breast tumors and breast cancer patient sera and is associated with poor clinical outcomes in breast cancer. These clinical associations are corroborated by emerging preclinical data revealing that IL-6 is a potent growth factor and promotes an epithelial-mesenchyme (EMT) phenotype in breast cancer cells to indicate that IL-6 in the breast tumor microenvironment is clinically relevant. High serum levels of interleukin-6 correlate with poor outcome in breast cancer patients. However, few data are yet available on the relationship between IL-6 and stem/progenitor cells, which may fuel the genesis of breast cancer in vivo. Mammospheres (MS) from node invasive breast carcinoma tissues express IL-6 mRNA at higher levels than MS from matched non-neoplastic mammary glands. IL-6 mRNA is detectable only in basal-like breast carcinoma tissues; our results reveal that IL-6 triggers a Notch-3-dependent upregulation of the Notch ligand Jagged-1, whose interaction with Notch-3 promotes the growth of MS and Michigan Cancer Foundation-7 (MCF-7)-derived spheroids. IL-6 induces a Notch-3-dependent upregulation of the carbonic anhydrase IX gene and promotes a hypoxia-resistant/invasive phenotype in MCF-7 cells and MS. In conclusion, our data support the hypothesis that IL-6 induces malignant features in Notch-3-expressing, stem/progenitor cells from human ductal breast carcinoma and normal mammary gland.
    World Journal of Surgical Oncology 03/2015; 13(1):129. DOI:10.1186/s12957-015-0529-2 · 1.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In 1998, a systemic fetal cytokine response, defined as a plasma interleukin-6 (IL-6) value above 11pg/mL, was reported to be a major independent risk factor for the subsequent development of neonatal morbid events even after adjustments for gestational age and other confounders. Since then, the body of literature investigating the use of blood concentrations of IL-6 as a hallmark of the fetal inflammatory response syndrome (FIRS), a diagnostic marker of early-onset neonatal sepsis (EONS) and a risk predictor of white matter injury (WMI), has grown rapidly. In this article, we critically review: IL-6 biological functions; current evidence on the association between IL-6, preterm birth, FIRS and EONS; IL-6 reference intervals and dynamics in the early neonatal period; IL-6 response during the immediate postnatal period and perinatal confounders; accuracy and completeness of IL-6 diagnostic studies for EONS (according to the Standards for Reporting of Diagnostic Accuracy statement); and recent breakthroughs in the association between fetal blood IL-6, EONS, and WMI. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Cytokine 04/2015; DOI:10.1016/j.cyto.2015.03.015 · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interaction of host cells with a biomaterial surface is important for biocompatibility and thus is essential for biomedical applications. Therefore investigations are undertaken to scrutinize for an appropriate surface coating with physical and chemical properties minimizing undesirable activation of immunological response. For this the current study was aimed at examining the effects of different surface modifications of titanium by its coating with ceramic materials - hydroxyapatite, bioglass and CaO-SiO2 on osteoblast morphology and secretory activity. Titanium is known for its excellent mechanical properties but its surface has low bioactivity. We report that CaO-SiO2 coating decreased a number of attached osteoblasts and altered their morphology. Moreover, the ceramic coatings temporarily upregulated release of pro-inflammatory cytokines IL-6 (all of them) and TNF-α (CaO-SiO2). However, overall the levels of the cytokines were low. In contrast, levels of neutrophil-attracting chemokine IL-8 were the highest. IL-8 was produced mostly by cells incubated with hydroxyapatite titanium coating in contrary to those incubated with either bioglass or CaO-SiO2 titanium modifications. In conclusion, the titanium coated with ceramics such as hydroxyapatite or bioglass had the best effect on cell adhesion; however, hydroxyapatite might potentially stimulate destructive neutrophils while CaO-SiO2-coating has a negative effect on cell adhesion.

Full-text (2 Sources)

Download
148 Downloads
Available from
Jun 3, 2014